- Home
- REFI vs VNDA Comparison
REFI vs VNDA Comparison
Compare REFI & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- VNDA
- Stock Information
- Founded
- REFI 2021
- VNDA 2002
- Country
- REFI United States
- VNDA United States
- Employees
- REFI N/A
- VNDA N/A
- Industry
- REFI Real Estate Investment Trusts
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- REFI Real Estate
- VNDA Health Care
- Exchange
- REFI Nasdaq
- VNDA Nasdaq
- Market Cap
- REFI 306.1M
- VNDA 270.2M
- IPO Year
- REFI 2021
- VNDA 2006
- Fundamental
- Price
- REFI $15.39
- VNDA $4.73
- Analyst Decision
- REFI Buy
- VNDA Buy
- Analyst Count
- REFI 2
- VNDA 1
- Target Price
- REFI $20.00
- VNDA $13.00
- AVG Volume (30 Days)
- REFI 73.0K
- VNDA 641.3K
- Earning Date
- REFI 11-07-2024
- VNDA 11-06-2024
- Dividend Yield
- REFI 12.22%
- VNDA N/A
- EPS Growth
- REFI N/A
- VNDA N/A
- EPS
- REFI 1.97
- VNDA N/A
- Revenue
- REFI $55,186,946.00
- VNDA $182,022,000.00
- Revenue This Year
- REFI N/A
- VNDA $6.70
- Revenue Next Year
- REFI $4.51
- VNDA $51.03
- P/E Ratio
- REFI $7.81
- VNDA N/A
- Revenue Growth
- REFI 5.63
- VNDA N/A
- 52 Week Low
- REFI $13.86
- VNDA $3.30
- 52 Week High
- REFI $17.65
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- REFI 42.89
- VNDA 48.57
- Support Level
- REFI $15.37
- VNDA $4.68
- Resistance Level
- REFI $15.85
- VNDA $4.98
- Average True Range (ATR)
- REFI 0.13
- VNDA 0.18
- MACD
- REFI -0.00
- VNDA 0.05
- Stochastic Oscillator
- REFI 22.22
- VNDA 40.00
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.